FOLH1 and neoplasm: For example, exploratory studies associated with a phase I clinical trial of PSMA CAR T cell therapy armored to express dominant-negative transforming growth factor-β receptor (TGFβR-DN) in mCRPC showed that the expression of immunosuppressive signaling molecules in the tumor microenvironment increases after CAR T infusion13.